Clinical Report: QUELL-DME Trial Gets Underway
Overview
The QUELL-DME trial has commenced, evaluating the oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema (DME). This Phase 2 study aims to enroll approximately 180 participants to assess the drug's efficacy as monotherapy and in combination with anti-VEGF therapy.
Background
Diabetic macular edema (DME) is a significant cause of vision loss in patients with diabetes, necessitating effective treatment options. Current management primarily involves intravitreal anti-VEGF therapy, which has shown superior outcomes compared to traditional laser treatments.
Data Highlights
The QUELL-DME trial will randomize participants 1:1:1 into three treatment groups: intravitreal anti-VEGF plus oral placebo, intravitreal anti-VEGF plus BGE-102 90 mg once daily, or sham intravitreal injection plus BGE-102 90 mg once daily. The primary endpoint is the change from baseline in best-corrected visual acuity (BCVA) at week 12, with topline results expected in the second half of 2027.
Key Findings
- The QUELL-DME trial is a Phase 2 study evaluating BGE-102 in adults with DME.
- Approximately 180 participants will be enrolled in the trial.
- BGE-102 will be assessed both as monotherapy and in combination with standard anti-VEGF therapy.
- The primary endpoint is the change in best-corrected visual acuity at week 12.
- Topline results are anticipated in the second half of 2027.
Clinical Implications
The initiation of the QUELL-DME trial represents a potential advancement in the treatment landscape for DME, particularly for patients who may require alternatives to repeated intravitreal injections. The outcomes of this trial could inform future therapeutic strategies targeting inflammatory pathways in diabetic retinal diseases.
Conclusion
The QUELL-DME trial marks a significant step in exploring the role of NLRP3 inhibition in treating DME, with the potential to enhance visual outcomes for affected patients.
Related Resources & Content
- Retinal Physician, Oral NLRP3 Inhibitor Enters DME Trial Recommendations, 2026 -- Oral NLRP3 Inhibitor Enters DME Trial
- Retinal Physician, OLN-324 Shows Extended Drying in DME, 2026 -- OLN-324 Shows Extended Drying in DME
- Retinal Physician, Clinical Trial Spotlight, 2008 -- Clinical Trial Spotlight
- S264 Retinopathy, Neuropathy, and Foot Care, Diabetes Care, 2026 -- Current guidance on DME management
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - PubMed, 2026 -- Aflibercept 8 mg trial results
- Retinal Physician — The Diabetic Retinopathy Pipeline
- S264 Retinopathy, Neuropathy, and Foot Care Diabetes Care Volume 49, Supplement 1, January 2026
- Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial - PubMed
- Advances in diagnosing and treating diabetic retinopathy | Nature Reviews Endocrinology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
